Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen

Autor: Natasha Strydom, Jacqueline P. Ernest, Marjorie Imperial, Belén P. Solans, Qianwen Wang, Rokeya Tasneen, Sandeep Tyagi, Heena Soni, Andrew Garcia, Kristina Bigelow, Martin Gengenbacher, Matthew Zimmerman, Min Xie, Jansy P. Sarathy, Tian J. Yang, Véronique Dartois, Eric L. Nuermberger, Radojka M. Savic

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)

Abstract TBI-223, a novel oxazolidinone for tuberculosis, is designed to provide improved efficacy and safety compared to linezolid in combination with bedaquiline and pretomanid (BPaL). We aim to optimize the dosing of TBI-223 within the BPaL regime

Externí odkaz: https://doaj.org/article/9d1084b5f6bc4812a0fc0f521bbba61f

A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study

Autor: Firat Kaya, Jacqueline P. Ernest, Katherine LoMauro, Martin Gengenbacher, Abdeldjalil Madani, Wassihun Wedajo Aragaw, Matthew D. Zimmerman, Jansy P. Sarathy, Nadine Alvarez, Isaac Daudelin, Han Wang, Faye Lanni, Danielle M. Weiner, Laura E. Via, Clifton E. Barry, Kenneth N. Olivier, Thomas Dick, Brendan K. Podell, Radojka M. Savic, Véronique Dartois

Publikováno v: Antimicrob Agents Chemother
Antimicrobial agents and chemotherapy, vol 66, iss 3

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a potentially fatal infectious disease requiring long treatment duration with multiple antibiotics and against which there is no reliable cure. Among the factors that have hampered the develo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73437e3bfdd6dc8ae59d4155e1b4de2e
https://doi.org/10.1128/aac.02212-21

Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection

Autor: Jacqueline P Ernest, Timothy R. Sterling, Rada M. Savic, Nan Zhang, Robert Belknap, Kendra K. Radtke, Nicole C. Ammerman, Rosanna Boyd, Eric L. Nuermberger

Publikováno v: Antimicrobial agents and chemotherapy, vol 65, iss 12
Antimicrobial Agents and Chemotherapy, 65(12):e01705-21. American Society for Microbiology
Antimicrob Agents Chemother

Rifapentine has facilitated treatment shortening for latent tuberculosis infection (LTBI) in combination with isoniazid once weekly for 3 months (3HP) or daily for 1 month (1HP). Our objective was to determine the optimal rifapentine dose for a 6-wee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e434301e6c33ea51f6be00d78a9853b
https://doi.org/10.1128/AAC.01705-21

Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis

Autor: Qianwen Wang, Véronique Dartois, Rada M. Savic, Natasha Strydom, Eric L. Nuermberger, Jacqueline P Ernest, Nan Zhang

Publikováno v: Annu Rev Pharmacol Toxicol
Annual review of pharmacology and toxicology, vol 61, iss 1

Tuberculosis (TB) kills more people than any other infectious disease. Challenges for developing better treatments include the complex pathology due to within-host immune dynamics, interpatient variability in disease severity and drug pharmacokinetic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c00850ba23c276bca7ed3827e9bdda94
https://pubmed.ncbi.nlm.nih.gov/32806997